2024
Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons
Swartwood N, Li Y, Regan M, Marks S, Barham T, Asay G, Cohen T, Hill A, Horsburgh C, Khan A, McCree D, Myles R, Salomon J, Self J, Menzies N. Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons. JAMA Network Open 2024, 7: e2431988. PMID: 39254977, PMCID: PMC11388029, DOI: 10.1001/jamanetworkopen.2024.31988.Peer-Reviewed Original ResearchConceptsUS-born personsEthnic disparitiesCase-fatality rateTB deathsTB casesTB incidenceSex-adjusted incidenceNational TB surveillance dataTB surveillance dataQuality-adjusted life yearsDistrict of ColumbiaTB disparitiesHealth outcomesEconomic outcomesFuture healthOutcome of TBUS-BornTB outcomesEstimate healthLife yearsSocietal costsTB burdenSocietal perspectiveGeneralized additive regression modelsGoal attainment
2023
Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States
Swartwood N, Testa C, Cohen T, Marks S, Hill A, Beeler Asay G, Cochran J, Cranston K, Randall L, Tibbs A, Horsburgh C, Salomon J, Menzies N. Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States. BMC Medicine 2023, 21: 331. PMID: 37649031, PMCID: PMC10469407, DOI: 10.1186/s12916-023-02785-y.Peer-Reviewed Original ResearchConceptsLatent tuberculosis infectionTB outcomesDistrict of ColumbiaTreatment of LTBIIncremental cost-effectiveness ratioTB incidence rateTuberculosis disease burdenQuality-adjusted life yearsCost-effectiveness ratioPublic health agenciesTB casesTB preventionTB incidenceTuberculosis infectionTB epidemiologyDisease burdenIncidence rateService utilizationAdditional interventionsIncidence projectionsLife yearsDemographic dataSocietal perspectiveHealth agenciesPrevention approaches
2021
T3 Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies sphingosine kinase 1 as a potential therapeutic target
Reichmann M, Tezera L, Vallejo A, Vukmirovic M, Xiao R, Jogai S, Wilson S, Marshall, Jones, Leslie A, D’Armiento J, Kaminski N, Polak M, Elkington P. T3 Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies sphingosine kinase 1 as a potential therapeutic target. Thorax 2021, 76: a2-a3. DOI: 10.1136/thorax-2021-btsabstracts.3.Peer-Reviewed Original ResearchPotential therapeutic targetTherapeutic targetTB granulomasHost-directed therapeutic targetHuman tuberculosis granulomasImmunopathology of tuberculosisPathological host responsesInflammatory immune responseSphingosine kinase 1 inhibitionInflammatory mediator secretionImmune-related phenomenaDisease-specific mechanismsNew therapeutic approachesHuman TB granulomasDose-dependent mannerKinase 1 inhibitionDunnett's multiple comparison testMultiple comparison testHuman cell culture modelsTB patientsLymph nodesSarcoidosis patientsTB outcomesClinical featuresTuberculosis granulomasIntegrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets
Reichmann MT, Tezera LB, Vallejo AF, Vukmirovic M, Xiao R, Reynolds J, Jogai S, Wilson S, Marshall B, Jones MG, Leslie A, D'Armiento JM, Kaminski N, Polak ME, Elkington P. Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets. Journal Of Clinical Investigation 2021, 131 PMID: 34128839, PMCID: PMC8321576, DOI: 10.1172/jci148136.Peer-Reviewed Original ResearchConceptsTherapeutic targetTB granulomasHuman TB diseaseHuman tuberculosis granulomasNoninfectious granulomatous diseasesPathological host responsesSarcoidosis lymph nodesInflammatory immune responseSphingosine kinase 1 inhibitionInflammatory mediator secretionPotential therapeutic targetHuman TB granulomasKinase 1 inhibitionHuman cell culture modelsInfected granulomasTB diseaseLymph nodesTB outcomesTuberculosis granulomasStandard treatmentSphingosine kinase 1Granulomatous diseaseLaser capture microdissectionMediator secretionExtensive infectionThe impact of COVID-19 on TB: a review of the data
McQuaid C, Vassall A, Cohen T, Fiekert K, COVID/TB Modelling Working Group *, White R. The impact of COVID-19 on TB: a review of the data. The International Journal Of Tuberculosis And Lung Disease 2021, 25: 436-446. PMID: 34049605, PMCID: PMC8171247, DOI: 10.5588/ijtld.21.0148.Peer-Reviewed Original ResearchBayesian evidence synthesis to estimate subnational TB incidence: An application in Brazil
Chitwood MH, Pelissari DM, da Silva G, Bartholomay P, Rocha MS, Sanchez M, Arakaki-Sanchez D, Glaziou P, Cohen T, Castro MC, Menzies NA. Bayesian evidence synthesis to estimate subnational TB incidence: An application in Brazil. Epidemics 2021, 35: 100443. PMID: 33676092, PMCID: PMC8252152, DOI: 10.1016/j.epidem.2021.100443.Peer-Reviewed Original ResearchConceptsTB incidenceFraction of casesUntreated active diseaseIncident TB casesTB control programsLocal disease burdenIncident TBActive diseaseTB burdenTB casesTB outcomesTB notificationsDisease burdenBayesian evidence synthesisCase detectionIncidenceEvidence synthesisAverage annual increaseControl programsBurdenAnnual rateAnnual increaseFraction of individualsAverage annual rateSources of bias
2018
2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector
Lee D, Kumarasamy N, Resch S, Sivaramakrishnan G, Mayer K, Tripathy S, Paltiel A, Freedberg K, Reddy K. 2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector. Open Forum Infectious Diseases 2018, 5: s582-s582. PMCID: PMC6254532, DOI: 10.1093/ofid/ofy210.1656.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioPublic healthcare facilitiesLife expectancyXpert MTB/RIFHIV-negative patientsPeripheral healthcare settingsHealthcare facilitiesBudgetary impact analysisMTB/RIFDiagnostic test costsSputum smear microscopyCost-effectiveness ratioMulti-way sensitivity analysesTB outcomesTB diagnosisPoint of careTruenatSmear microscopyXpertBudget impactTuberculosis diagnosticsDiagnostic strategiesHealthcare expendituresHealthcare settingsRifampin resistance
2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal Of Antimicrobial Chemotherapy 2006, 58: 1299-1302. PMID: 17032686, DOI: 10.1093/jac/dkl399.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAnti-HIV AgentsAntibiotics, AntitubercularBenzoxazinesCD4 Lymphocyte CountChromatography, High Pressure LiquidCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineLongitudinal StudiesMaleOxazinesRifampinTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsExcellent clinical outcomesEfavirenz concentrationsClinical outcomesAntiretroviral therapyEfavirenz levelsAfrican patientsNon-detectable viral loadSmear-positive pulmonary TBLong-term clinical outcomesAdministration of efavirenzCD4 cell increaseHIV clinical outcomesPlasma efavirenz concentrationsCells/mm3Half of patientsTB regimenPulmonary TBPharmacokinetic interactionsTB outcomesTherapy completionRifampicin administrationViral loadTherapeutic rangePatientsHIV
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply